Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy.
Evangelos TerposMaria GavriatopoulouIoannis Ntanasis-StathopoulosAlexandros BriasoulisSentiljana GumeniPanagiotis MalandrakisEleni-Dimitra PapanagnouMagdalini MigkouNikolaos KanelliasEfstathios KastritisIoannis P TrougakosMeletios A DimopoulosPublished in: Blood (2022)